Changchun High-Tech Industry (000661.SZ): GenSci128 Tablets Granted Orphan Drug Designation by the US FDA
Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received notification from the US Food and Drug Administration (FDA) granting orphan drug designation to GenSci128 tablets for the treatment of stomach cancer.
Changchun High-Tech Industry (000661.SZ) announced that its subsidiary, Changchun GenSci Pharmaceutical Co., Ltd. (referred to as "GenSci Pharmaceutical"), has received notification from the Food and Drug Administration (FDA) of the United States that GenSci 128 tablets have been granted orphan drug designation for the treatment of gastric cancer.
Related Articles
NOIZ GROUP (08163) issues a profit warning, expecting a net loss of approximately HK$9 million to HK$15 million for the fiscal year 2025.
STAR GROUP ASIA (01560) issues profit warning. It is expected that the company's equity holders' losses for the year 2025 will narrow by approximately 299.3 million Hong Kong dollars compared to the previous year.
ESUN HOLDINGS (00571) announced its interim results, with a profit attributable to shareholders of HK$9.333 million, turning losses into gains year-on-year.
NOIZ GROUP (08163) issues a profit warning, expecting a net loss of approximately HK$9 million to HK$15 million for the fiscal year 2025.
STAR GROUP ASIA (01560) issues profit warning. It is expected that the company's equity holders' losses for the year 2025 will narrow by approximately 299.3 million Hong Kong dollars compared to the previous year.
ESUN HOLDINGS (00571) announced its interim results, with a profit attributable to shareholders of HK$9.333 million, turning losses into gains year-on-year.
